23 results on '"Webb, John G."'
Search Results
2. Sex-Related Outcomes of Transcatheter Aortic Valve Implantation With Self-Expanding or Balloon-Expandable Valves: Insights from the OPERA-TAVI Registry
- Author
-
Adamo, Marianna, Branca, Luca, Pezzola, Elisa, Saia, Francesco, Pilgrim, Thomas, Abdel-Wahab, Mohamed, Garot, Philippe, Gandolfo, Caterina, Fiorina, Claudia, Sammartino, Sofia, Latib, Azeem, Santos, Ignacio Amat, Mylotte, Darren, De Marco, Federico, De Backer, Ole, Franco, Luis Nombela, Akodad, Mariama, Ribichini, Flavio Luciano, Bedogni, Francesco, Laterra, Giulia, Mazzapicchi, Alessandro, Tomii, Daijiro, Laforgia, Pietro, Cannata, Stefano, Scotti, Andrea, Fezzi, Simone, Criscione, Enrico, Poletti, Enrico, Mazzucca, Mattia, Valvo, Roberto, Lunardi, Mattia, Mainardi, Andrea, Andreaggi, Stefano, Quagliana, Angelo, Montarello, Nicholas, Hennessey, Breda, Mon-Noboa, Matias, Meier, David, Sgroi, Carmelo, Reddavid, Claudia Maria, Strazzieri, Orazio, Motta, Silvia Crescenzia, Frittitta, Valentina, Dipietro, Elena, Comis, Alessandro, Melfa, Chiara, Cal, Mariachiara, Thiele, Holger, Webb, John G., Søndergaard, Lars, Tamburino, Corrado, Metra, Marco, Costa, Giuliano, and Barbanti, Marco
- Published
- 2024
- Full Text
- View/download PDF
3. Outcomes After Transcatheter Mitral Valve Replacement According to Regurgitation Etiology
- Author
-
Perrin, Nils, Ben-Ali, Walid, Ludwig, Sebastian, Duncan, Alison, Weimann, Jessica, Nickenig, Georg, Tanaka, Tetsu, Coisne, Augustin, Vincentelli, Andre, Makkar, Raj, Webb, John G., Akodad, Mariama, Muller, David W.M., Jansz, Paul, Praz, Fabien, Reineke, David, Wild, Mirjam G., Hausleiter, Jörg, Goel, Sachin S., Denti, Paolo, Chehab, Omar, Dahle, Gry, Baldus, Stephan, Ruge, Hendrik, Kaneko, Tsuyoshi, Ternacle, Julien, Dumonteil, Nicolas, von Bardeleben, Ralph Stephan, Flagiello, Michele, Walther, Thomas, Taramasso, Maurizio, Søndergaard, Lars, Bleiziffer, Sabine, Fam, Neil, Kempfert, Joerg, Granada, Juan F., Tang, Gilbert H.L., Conradi, Lenard, and Modine, Thomas
- Published
- 2024
- Full Text
- View/download PDF
4. The Impact of Cerebral Embolic Protection Devices on Characteristics and Outcomes of Stroke Complicating TAVR
- Author
-
Levi, Amos, Linder, Matthias, Seiffert, Moritz, Witberg, Guy, Pilgrim, Thomas, Tomii, Daijiro, Barkan, Yeela Tamlor, Van Mieghem, Nicolas M., Adrichem, Rik, Codner, Pablo, Hildick-Smith, David, Arunothayaraj, Sandeep, Perl, Leor, Finkelstein, Ariel, Loewenstein, Itamar, De Backer, Ole, Barnea, Rani, Tarantini, Giuseppe, Fovino, Luca Nai, Vaknin-Assa, Hana, Mylotte, Darren, Wagener, Max, Webb, John G., Akodad, Mariama, Colombo, Antonio, Mangieri, Antonio, Latib, Azeem, Kargoli, Faraj, Giannini, Francesco, Ielasi, Alfonso, Søndergaard, Lars, Aviram, Itay, Lerman, Tsahi T., Kheifets, Mark, Auriel, Eitan, and Kornowski, Ran
- Published
- 2024
- Full Text
- View/download PDF
5. Impact of the COVID-19 Pandemic on Global TAVR Activity: The COVID-TAVI Study
- Author
-
Armario, Xavier, Carron, Jennifer, Simpkin, Andrew J., Elhadi, Mohamed, Kennedy, Ciara, Abdel-Wahab, Mohamed, Bleiziffer, Sabine, Lefèvre, Thierry, Wolf, Alexander, Pilgrim, Thomas, Villablanca, Pedro A., Blackman, Daniel J., Van Mieghem, Nicolas M., Hengstenberg, Christian, Swaans, Martin J., Prendergast, Bernard D., Patterson, Tiffany, Barbanti, Marco, Webb, John G., Behan, Miles, Resar, Jon, Chen, Mao, Hildick-Smith, David, Spence, Mark S., Zweiker, David, Bagur, Rodrigo, Teles, Rui, Ribichini, Flavio L., Jagielak, Dariusz, Park, Duk-Woo, Kornowski, Ran, Wykrzykowska, Joanna J., Bunc, Matjaz, Estévez-Loureiro, Rodrigo, Poon, Karl, Götberg, Matthias, Jeger, Raban V., Ince, Hüseyin, Packer, Erik J.S., Angelillis, Marco, Nombela-Franco, Luis, Guo, Yingqiang, Savontaus, Mikko, Al-Moghairi, Abdulrahman M., Parasca, Catalina Andreea, Kliger, Chad, Roy, David, Molnár, Levente, Silva, Mariana, White, Jonathon, Yamamoto, Masanori, Carrilho-Ferreira, Pedro, Toggweiler, Stefan, Voudris, Vassileios, Ohno, Yohei, Rodrigues, Inês, Parma, Radosław, Ojeda, Soledad, Toutouzas, Kostas, Regueiro, Ander, Grygier, Marek, AlMerri, Khaled, Cruz-González, Ignacio, Fridrich, Viliam, de la Torre Hernández, José M., Noble, Stephane, Kala, Petr, Asmarats, Lluis, Kurt, Ibrahim Halil, Bosmans, Johan, Erglis, Martins, Casserly, Ivan, Iskandarani, Dounia, Bhindi, Ravinay, Kefer, Joelle, Yin, Wei-Hsian, Rosseel, Liesbeth, Kim, Hyo-Soo, O'Connor, Stephen, Hellig, Farrel, Sztejfman, Matias, Mendiz, Oscar, Pineda, Andres M., Seth, Ashok, Pllaha, Elton, de Brito, Fabio S., Jr., Bajoras, Vilhelmas, Balghith, Mohammed A., Lee, Michael, Eid-Lidt, Guering, Vandeloo, Bert, Vaz, Vinicius Daher, Alasnag, Mirvat, Ussia, Gian Paolo, Tay, Edgar, Mayol, Jorge, Gunasekaran, Sengottuvelu, Sardella, Gennaro, Buddhari, Wacin, Kao, Hsien-Li, Dager, Antonio, Tzikas, Apostolos, Gudmundsdottir, Ingibjörg J., Edris, Ahmad, Gutiérrez Jaikel, Luis Abel, Arias, Eduardo A., Al-Hijji, Mohammed, Ertürk, Mehmet, Conde-Vela, César, Boljević, Darko, Ferrero Guadagnoli, Adolfo, Hermlin, Toomas, ElGuindy, Ahmed M., Lima-Filho, Moysés de Oliveira, de Moura Santos, Luciano, Perez, Luis, Maluenda, Gabriel, Akyüz, Ali Rıza, Alhaddad, Imad A., Amin, Haitham, So, Chak-Yu, Al Nooryani, Arif A., Vaca, Carlos, Albistur, Juan, Nguyen, Quang Ngoc, Arzamendi, Dabit, Grube, Eberhard, Modine, Thomas, Tchétché, Didier, Hayashida, Kentaro, Latib, Azeem, Makkar, Raj R., Piazza, Nicolo, Søndergaard, Lars, McEvoy, John William, and Mylotte, Darren
- Published
- 2024
- Full Text
- View/download PDF
6. Long-term outcomes and device failure after TAVI
- Author
-
Barbanti, Marco and Webb, John G.
- Published
- 2024
- Full Text
- View/download PDF
7. An Optimized Assessment Pathway for Remote Patients: The Vancouver Facilitated Transcatheter Aortic Valve Implantation Program
- Author
-
Husain, Ali, Jelisejevas, Julius, Chatfield, Andrew, Akodad, Mariama, Lauck, Sandra B., Achtem, Leslie, Tang, Erin, Zaky, Fady, Blanke, Philipp, Leipsic, Jonathan, Sellers, Stephanie L., Ye, Jian, Cheung, Anson, Moss, Robert, Wood, David, Boone, Robert, Meier, David, Sathananthan, Janarthanan, and Webb, John G.
- Published
- 2024
- Full Text
- View/download PDF
8. Sex-differences in Newly Diagnosed Severe Aortic Stenosis in British Columbia (B.C.) between 2012 - 2022
- Author
-
Roshan, Aishwarya, primary, Yim, Jeffrey, additional, Lakhani, Shamikh, additional, Wang, Jennifer, additional, Sidhu, Aamiya, additional, Sayre, Eric C., additional, Humphries, Karin, additional, Sathananthan, Janarthanan, additional, Wood, David A., additional, Tsang, Michael Yin-Cheung, additional, Yeung, Darwin F., additional, Luong, Christina, additional, Nair, Parvathy, additional, Gin, Kenneth, additional, Jue, John, additional, Webb, John G., additional, and Tsang, Teresa S.M., additional
- Published
- 2024
- Full Text
- View/download PDF
9. Predictors and 5-Year Clinical Outcomes of Pacemaker After TAVR
- Author
-
Chen, Shmuel, primary, Dizon, Jose M., additional, Hahn, Rebecca T., additional, Pibarot, Philippe, additional, George, Isaac, additional, Zhao, Yanglu, additional, Blanke, Philipp, additional, Kapadia, Samir, additional, Babaliaros, Vasilis, additional, Szeto, Wilson Y., additional, Makkar, Raj, additional, Thourani, Vinod H., additional, Webb, John G., additional, Mack, Michael J., additional, Leon, Martin B., additional, Kodali, Susheel, additional, and Nazif, Tamim M., additional
- Published
- 2024
- Full Text
- View/download PDF
10. Hydrodynamic Assessment of Explanted Degenerated Transcatheter Aortic Valves
- Author
-
Sathananthan, Janarthanan, primary, Nigade, Anish, additional, Meier, David, additional, Navarro, Dante, additional, Spencer, Julianne, additional, Lai, Althea, additional, Gill, Hacina, additional, Pirelli, Luigi, additional, Webb, John G., additional, Wood, David A., additional, Lutter, Georg, additional, Puehler, Thomas, additional, Tang, Gilbert H.L., additional, Fukuhara, Shinichi, additional, and Sellers, Stephanie L., additional
- Published
- 2024
- Full Text
- View/download PDF
11. Osteosarcopenia and Mortality in Older Adults Undergoing Transcatheter Aortic Valve Replacement
- Author
-
Solla-Suarez, Pablo, primary, Arif, Saleena Gul, additional, Ahmad, Fayeza, additional, Rastogi, Neelabh, additional, Meng, Andrew, additional, Cohen, Joshua M., additional, Rodighiero, Julia, additional, Piazza, Nicolo, additional, Martucci, Giuseppe, additional, Lauck, Sandra, additional, Webb, John G., additional, Kim, Dae H., additional, Kovacina, Bojan, additional, and Afilalo, Jonathan, additional
- Published
- 2024
- Full Text
- View/download PDF
12. EVOQUE Tricuspid Valve Replacement System: State-of-the-Art Screening and Intraprocedural Guidance.
- Author
-
Hahn, Rebecca T., Makkar, Raj, Makar, Moody, Davidson, Charles, Puthamana, Jyothy, Zahr, Firas, Chadderdon, Scott, Fam, Neil, Ong, Geraldine, Yadav, Pradeep K., Thourani, Vinod H., Vannan, Mani A., Tchétché, Didier, Dumonteil, Nicolas, Bonfils, Laurent, Lepage, Laurent, Smith, Robert, Grayburn, Paul A., Webb, John G., and Moss, Robert
- Published
- 2024
- Full Text
- View/download PDF
13. Redo-TAVI with the ACURATE neo2 and Prime XL for balloon-expandable transcatheter heart valve failure
- Author
-
Meier, David, primary, Grant, Daire, additional, Frawley, Chris, additional, Akodad, Mariama, additional, Landes, Uri, additional, Kokhar, Arif A., additional, Dudek, Dariusz, additional, George, Isaac, additional, Rinaldi, Michael J., additional, Kim, Won-Keun, additional, Yakubov, Steven J., additional, Sorajja, Paul, additional, Tarantini, Giuseppe, additional, Wood, David A., additional, Webb, John G., additional, Sellers, Stephanie L., additional, and Sathananthan, Janarthanan, additional
- Published
- 2024
- Full Text
- View/download PDF
14. Transcatheter Mitral Valve-in-Valve Replacement in the Presence of Pannus
- Author
-
Jelisejevas, Julius, primary, Husain, Ali, additional, Dundas, James, additional, Chiang, Brian, additional, Akodad, Mariama, additional, Zaky, Fady, additional, Sathananthan, Gnalini, additional, Wood, David A., additional, Leipsic, Jonathon A., additional, Blanke, Philipp, additional, Sathananthan, Janarthanan, additional, Sellers, Stephanie L., additional, Meier, David, additional, and Webb, John G., additional
- Published
- 2024
- Full Text
- View/download PDF
15. Transcatheter Tricuspid Valve Replacement to Treat Failed Transcatheter Edge-to-Edge Repair.
- Author
-
Cheung, Anson, Offen, Sophie, Husain, Ali, Chiang, Brian, Ferkh, Aaisha, Meier, David, Madden, Anne-Marie, Blanke, Philipp, Webb, John G., and Boone, Robert
- Published
- 2024
- Full Text
- View/download PDF
16. Early mobilization after transcatheter aortic valve implantation: observational cohort study.
- Author
-
Lauck, Sandra B, Yu, Maggie, Bancroft, Carrie, Borregaard, Britt, Polderman, Jopie, Stephenson, Anna L, Durand, Eric, Akodad, Mariama, Meier, David, Andrews, Holly, Achtem, Leslie, Tang, Erin, Wood, David A, Sathananthan, Janarthanan, and Webb, John G
- Subjects
MEDICAL protocols ,RESEARCH funding ,T-test (Statistics) ,SCIENTIFIC observation ,FISHER exact test ,EARLY ambulation (Rehabilitation) ,NURSING ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,CHI-squared test ,HEART valve prosthesis implantation ,LONGITUDINAL method ,DATA analysis software ,CONFIDENCE intervals - Abstract
Aims Early mobilization is associated with improved outcomes in hospitalized older patients. We sought to determine the effect of a nurse-led protocol on mobilization 4 h after transfemoral transcatheter aortic valve implantation (TAVI) across different units of care. Methods and results We conducted a prospective observational cohort single-centre study of consecutive patients. We implemented a standardized protocol for safe early recovery and progressive mobilization in the critical care and cardiac telemetry units. We measured the time to first mobilization and conducted descriptive statistics to identify patient and system barriers to timely ambulation. We recruited 139 patients (82.5 years, SD = 6.7; 46% women). At baseline, patients who were mobilized early (≤4 h) and late (>4 h) did not differ, except for higher rates of diabetes (25.5% vs. 43.9%, P = 0.032) and peripheral arterial disease (8.2% vs. 26.8%, P = 0.003) in the late mobilization group. The median time to mobilization was 4 h [inter-quartile range (IQR) 3.25, 4]; 98 patients (70.5%) were mobilized successfully after 4 h of bedrest; 118 (84.9%) were walking by the evening of the procedure (<8 h bedrest); and 21 (15.1%) were on bedrest overnight and mobilized the following day. Primary reasons for overnight bedrest were arrhythmia monitoring (n = 10, 7.2%) and haemodynamic and/or neurological instability (n = 6, 4.3%); six patients (4.3%) experienced delayed ambulation due to system issues. Procedure location in the hybrid operating room and transfer to critical care were associated with longer bedrest times. Conclusion Standardized nurse-led mobilization 4 h after TF TAVI is feasible in the absence of clinical complications and system barriers. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. TRIVALVE Score: A Risk Score for Mortality/Hospitalization Prediction in Patients Undergoing Transcatheter Tricuspid Valve Intervention.
- Author
-
Russo G, Pedicino D, Pires Marafon D, Adamo M, Alessandrini H, Andreas M, Braun D, Connelly KA, Denti P, Estevez-Loureiro R, Fam N, Hahn RT, Harr C, Hausleiter J, Himbert D, Kalbacher D, Ho E, Latib A, Lentini N, Lubos E, Ludwig S, Lurz P, Metra M, Monivas V, Nickenig G, Pastorino R, Pedrazzini G, Pozzoli A, Praz F, Rodes-Cabau J, Besler C, Rommel KP, Schofer J, Scotti A, Piayda K, Sievert H, Tang GHL, Thiele H, Schlotter F, von Bardeleben RS, Webb JG, Windecker S, Leon M, Enriquez-Sarano M, Maisano F, Crea F, and Taramasso M
- Subjects
- Humans, Risk Assessment, Male, Female, Risk Factors, Aged, Time Factors, Aged, 80 and over, Treatment Outcome, Reproducibility of Results, Clinical Decision-Making, Middle Aged, Predictive Value of Tests, Registries, Tricuspid Valve physiopathology, Tricuspid Valve diagnostic imaging, Tricuspid Valve surgery, Patient Readmission, Tricuspid Valve Insufficiency mortality, Tricuspid Valve Insufficiency physiopathology, Tricuspid Valve Insufficiency diagnostic imaging, Tricuspid Valve Insufficiency surgery, Cardiac Catheterization adverse effects, Cardiac Catheterization mortality, Cardiac Catheterization instrumentation, Decision Support Techniques, Heart Valve Prosthesis Implantation adverse effects, Heart Valve Prosthesis Implantation mortality, Heart Valve Prosthesis Implantation instrumentation, Severity of Illness Index
- Abstract
Background: Transcatheter tricuspid valve intervention (TTVI) has been increasingly adopted in recent years for the treatment of patients with tricuspid regurgitation (TR). However, no dedicated risk stratification has been established for patients undergoing TTVI., Objectives: The aim of the present study was to propose a dedicated risk score for patients affected by severe TR undergoing TTVI., Methods: The score was derived from the TRIVALVE (International Multisite Transcatheter Tricuspid Valve Therapies Registry; NCT03416166) registry, according to data availability. A stepwise model approach was used on predictor variables to develop a scoring system for predicting 12-month mortality or rehospitalization using multivariable logistic regression. Internal discrimination, calibration, and validation were assessed using receiver-operating characteristic curve analysis and bootstrapping with 1,000 resamples., Results: A total of 483 patients were included in the study, with an overall 12-month mortality or rehospitalization rate of 19% (n = 94). The final risk score, ranging from 0 to 4.5, included the following 5 parameters (adjusted for age and gender): 1) atrial fibrillation at baseline; 2) glomerular filtration rate <30 mL/min; 3) elevated gamma-glutamyl transferase/bilirubin levels; 4) signs of right heart failure; and 5) left ventricular ejection fraction <50%. The bias-corrected area under the receiver-operating characteristic curve was 68% (95% CI: 62%-75%). A cutoff value of 2.5 demonstrated sensitivity of 65.4% and specificity of 60.5% for the outcome., Conclusions: The present study proposes a dedicated risk score for patients undergoing TTVI, providing an additional and simple tool for heart teams to select the best therapy for patients affected by severe TR., Competing Interests: Funding Support and Author Disclosures Dr Russo has received a fellowship training grant from the European Association of Percutaneous Cardiovascular Interventions, sponsored by Edwards Lifesciences. Dr Adamo has received personal fees from Abbott Vascular, Medtronic, and Novartis. Dr Hahn has received speaker fees from Abbott Structural, Baylis Medical, Edwards Lifesciences, and Philips Healthcare; has institutional consulting contracts for which she receives no direct compensation with Abbott Structural, Boston Scientific, Edwards Lifesciences, Medtronic, and Novartis; has stock options with NaviGate; and is chief scientific officer for the Echocardiography Core Laboratory at the Cardiovascular Research Foundation for multiple industry-sponsored trials, for which she receives no direct industry compensation. Dr Andreas is a proctor, consultant, and speaker for Edwards Lifesciences, Abbott, Medtronic, Boston Scientific, and Zoll; and has received institutional research grants from Edwards Lifesciences, Abbott, Medtronic, and LSI Solutions. Dr Denti has received speaker honoraria from Abbott and Edwards Lifesciences. Dr Estevez-Loureiro is a consultant for Abbott Vascular, Boston Scientific, and Edwards Lifesciences. Dr Nickenig has received honoraria for lectures or advisory board membership from Abbott, Boston Scientific, Edwards Lifesciences, and Medtronic. Dr Schofer is a consultant for Edwards Lifesciences. Dr Sievert has received study honoraria to the institution, travel expenses, and consulting fees from 4tech Cardio, Abbott, Ablative Solutions, Adona Medical, Akura Medical, Ancora Heart, Append Medical, Axon, Bavaria Medizin Technologie, Bioventrix, Boston Scientific, Cardiac Dimensions, Cardiac Success, Cardimed, Cardionovum, CeloNova Biosciences, Contego, Coramaze, CroíValve, CSL Behring, CVRx, Dinova, Edwards Lifesciences, EndoBar, Endologix, EndoMatic, Esperion Therapeutics, Hangzhou Nuomao Medtech, Holistick Medical, InterShunt Technologies, Intervene, K2, Laminar, Life Tech Care, Magenta, Maquet Getinge Group, Metavention, Mitralix, Mokita, Neurotronic, NXT Biomedical, Occlutech, Recor, Renal Guard, Shifamed, Terumo, Trisol, Vascular Dynamics, Vectorious Medtech, Venus, Venock, Vivasure Medical, Vvital Biomed, and WhiteSwell. Dr Tang has served as a physician proctor for Medtronic; has served as a consultant for Medtronic, Abbott Structural Heart, and NeoChord; has served on the transcatheter aortic valve replacement advisory board for Abbott Structural Heart; and has served on the physician advisory board for JenaValve. Dr von Bardeleben has served for trials and as a principal investigator for Abbott, Edwards Lifesciences, and Medtronic. Dr Windecker has received research, travel, or educational grants to the institution from Abbott, Abiomed, Amgen, AstraZeneca, Bayer, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardinal Health, Cardiovalve, CorFlow Therapeutics, CSL Behring, Daiichi-Sankyo, Edwards Lifesciences, Guerbet, Infraredx, Janssen-Cilag, Johnson & Johnson, Medicure, Medtronic, Merck Sharp & Dohme, Miracor Medical, Novartis, Novo Nordisk, Organon, OrPha Suisse, Pfizer, Polares, Regeneron, Sanofi, Servier, Sinomed, Terumo, Vifor, and V-Wave; has served as an advisory board member and/or a member of the steering or executive groups of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, Bayer, Boston Scientific, Biotronik, Bristol Myers Squibb, Edwards Lifesciences, Janssen, MedAlliance, Medtronic, Novartis, Polares, Recardio, Sinomed, Terumo, V-Wave, and Xeltis, with payments to the institution but no personal payments; and is a member of the steering or executive committee groups of several investigator-initiated trials that receive funding from industry, without impact on his personal remuneration. Dr Enriquez-Sarano is a consultant for Edwards Lifesciences, ChemImage, Cryolife, and HighLife. Dr Maisano is a consultant for Abbott Vascular, Medtronic, Edwards Lifesciences, Perifect, Xeltis, Transseptal Solutions, Magenta, and Cardiovalve; has received grant support from Abbott Vascular, Medtronic, Edwards Lifesciences, Biotronik, Boston Scientific, NVT, and Terumo; has received royalties from Edwards Lifesciences and 4Tech; and is a cofounder and shareholder of Transseptal Solutions, 4Tech, Cardiovalve, Magenta, Perifect, Coregard and SwissVortex. Dr Taramasso has received consultancy fees from Abbott Vascular, Edwards Lifesciences, 4Tech, Boston Scientific, CoreMedic, Mitraltech, and SwissVortex (outside the submitted work). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
18. Left and right ventricular longitudinal systolic function following aortic valve replacement in the PARTNER 2 trial and registry.
- Author
-
Silva I, Ternacle J, Hahn RT, Salah-Annabi M, Dahou A, Krapf L, Salaun E, Guzzetti E, Xu K, Clavel MA, Bernier M, Beaudoin J, Cremer PC, Jaber W, Rodriguez L, Asch FM, Weismann NJ, Bax J, Ajmone N, Alu MC, Kallel F, Mack MJ, Webb JG, Kapadia S, Makkar R, Kodali S, Herrmann HC, Thourani V, Leon MB, and Pibarot P
- Subjects
- Humans, Male, Female, Aged, Transcatheter Aortic Valve Replacement adverse effects, Transcatheter Aortic Valve Replacement methods, Risk Assessment, Systole, Aged, 80 and over, Treatment Outcome, Stroke Volume physiology, Echocardiography, Ventricular Dysfunction, Left diagnostic imaging, Ventricular Dysfunction, Left physiopathology, Registries, Aortic Valve Stenosis surgery, Aortic Valve Stenosis diagnostic imaging, Aortic Valve Stenosis physiopathology, Heart Valve Prosthesis Implantation methods, Heart Valve Prosthesis Implantation adverse effects
- Abstract
Aims: Evaluation of left and right ventricular (RV) longitudinal systolic function may enhance risk stratification following aortic valve replacement (AVR). The study objective was to evaluate the changes in left and RV longitudinal systolic function and RV-pulmonary artery (RV-PA) coupling from baseline to 30 days and 1 year after AVR., Methods and Results: Left ventricular (LV) longitudinal strain (LS), tricuspid annulus plane systolic excursion (TAPSE), and RV-PA coupling were evaluated in patients from the PARTNER 2A surgical AVR (SAVR) arm (n = 985) and from the PARTNER 2 SAPIEN 3 registry (n = 719). TAPSE and RV-PA coupling decreased significantly following SAVR, but remained stable following TAVR. Lower LV LS, TAPSE, or RV-PA coupling at baseline was associated with increased risk of the composite of death, hospitalization, and stroke at 5 years [adjusted hazard ratios (HRs) for LV LS < 15%: 1.24, 95% confidence interval (CI) 1.05-1.45, P = 0.001; TAPSE < 14 mm: 1.44, 95% CI 1.21-1.73, P < 0.001; RV-PA coupling < 0.55 mm/mmHg: 1.32, 95% CI 1.07-1.63, P = 0.011]. Reduced TAPSE at baseline was the most powerful predictor of the composite endpoint at 5 years. Patients with LV ejection fraction <50% at baseline had increased risk of the primary endpoint with SAVR (HR: 1.34, 95% CI 1.08-1.68, P = 0.009) but not with TAVR (HR: 1.12, 95% CI 0.88-1.42). Lower RV-PA coupling at 30 days showed the strongest association with cardiac mortality., Conclusion: SAVR but not TAVR was associated with a marked deterioration in RV longitudinal systolic function and RV-PA coupling. Lower TAPSE and RV-PA coupling at 30 days were associated with inferior clinical outcomes at 5 years. In patients with LVEF < 50%, TAVR was associated with superior 5-year outcomes., Competing Interests: Conflict of interest: J.T. is consultant for Abbott, Philips Healthcare, and General Electric. R.T.H. reports speaker fees from Abbott Structural, Baylis Medical, Edwards Lifesciences, Medtronic, and Philips Healthcare; she has institutional consulting contracts for which she receives no direct compensation with Abbott Structural, Edwards Lifesciences, Medtronic, and Novartis; she is Chief Scientific Officer for the Echocardiography Core Laboratory at the Cardiovascular Research Foundation for multiple industry-sponsored tricuspid valve trials, for which she receives no direct industry compensation. M.-A.C. has research grant with Medtronic and core laboratory contract with Edwards Lifesciences without direct compensation. W.J. is consultant for Boston Scientific and BridgeBio. F.M.A. and N.J.W. have institutional research grants as directors of an academic core lab from Edwards, Abbott, Medtronic, Boston Scientific, Biotronik, Corcyn, and Foldax. They have no personal disclosures. N.A. received speakers fees from Abbott Vascular, GE Healthcare, and Philips ultrasound and research grants from Alnylam and Pfizer. H.C.H. reports institutional research funding from Abbott, Boston Scientific, Edwards Lifesciences, Highlife, Medtronic, and WL Gore; consulting fees from Edwards Lifesciences, Medtronic, Wells Fargo, and WL Gore; and equity in Holistick Medical and Micro Interventional Devices. M.J.M. has served as a Co-Pi for clinical trials for Abbott and Edwards Lifesciences and as Study Chair for a trial for Medtronic. All roles were uncompensated. V.T. is consultant or researcher for Abbott Vascular, Boston Scientific, CryoLife, Edwards Lifesciences, Medtronic, and Shockwave. The other authors have nothing to disclose., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
19. Double-tap to treat paravalvular leak in high-risk annuli.
- Author
-
Husain A, Jelisejevas J, Khoo JK, Akodad M, Chatfield A, Zaky F, Sellers SL, Leipsic JA, Blanke P, Wood DA, Meier D, Sathananthan J, and Webb JG
- Subjects
- Humans, Mitral Valve surgery, Mitral Valve diagnostic imaging, Mitral Valve physiopathology, Mitral Valve Insufficiency surgery, Mitral Valve Insufficiency diagnostic imaging, Mitral Valve Insufficiency physiopathology, Treatment Outcome, Prosthesis Failure, Female, Male, Cardiac Catheterization instrumentation, Cardiac Catheterization methods, Cardiac Catheterization adverse effects, Aged, Echocardiography, Transesophageal, Heart Valve Prosthesis Implantation instrumentation, Heart Valve Prosthesis Implantation adverse effects, Heart Valve Prosthesis Implantation methods, Heart Valve Prosthesis adverse effects
- Published
- 2024
- Full Text
- View/download PDF
20. Concomitant left atrial appendage occlusion in patients undergoing mitral transcatheter edge-to-edge repair: pros and cons.
- Author
-
Nietlispach F, Webb JG, and De Backer O
- Subjects
- Humans, Treatment Outcome, Heart Valve Prosthesis Implantation methods, Heart Valve Prosthesis Implantation adverse effects, Heart Valve Prosthesis Implantation instrumentation, Atrial Fibrillation surgery, Atrial Fibrillation complications, Atrial Fibrillation therapy, Atrial Appendage surgery, Atrial Appendage physiopathology, Atrial Appendage diagnostic imaging, Cardiac Catheterization methods, Cardiac Catheterization instrumentation, Cardiac Catheterization adverse effects, Mitral Valve Insufficiency surgery, Mitral Valve Insufficiency diagnostic imaging, Mitral Valve Insufficiency physiopathology, Mitral Valve surgery, Mitral Valve diagnostic imaging, Mitral Valve physiopathology
- Published
- 2024
- Full Text
- View/download PDF
21. Editorial: Decreasing pacemaker implantation rates with Evolut supra-annular transcatheter aortic valves.
- Author
-
Webb JG and Millar K
- Abstract
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: John G. Webb reports a relationship with Edwards Lifesciences Corporation that includes: consulting or advisory and funding grants. John G. Webb reports a relationship with Medtronic Inc. that includes: funding grants. John G. Webb reports a relationship with Boston Scientific Corporation that includes: funding grants. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
- Published
- 2024
- Full Text
- View/download PDF
22. Defining high bleeding risk in patients undergoing transcatheter aortic valve implantation: a VARC-HBR consensus document.
- Author
-
Garot P, Morice MC, Angiolillo DJ, Cabau JR, Park DW, Van Mieghem NM, Collet JP, Leon MB, Sengottuvelu G, Neylon A, Ten Berg JM, Mylotte D, Tchétché D, Krucoff MW, Reardon MJ, Piazza N, Mack MJ, Généreux P, Makkar R, Hayashida K, Ohno Y, Mochizuki S, Shirai Y, Matsumara R, Jin Y, Webb JG, Cutlip DE, Chen M, Spitzer E, Mehran R, and Capodanno D
- Subjects
- Humans, Risk Factors, Risk Assessment, Aortic Valve Stenosis surgery, Aortic Valve surgery, Transcatheter Aortic Valve Replacement adverse effects, Consensus, Hemorrhage etiology
- Abstract
The identification and management of patients at high bleeding risk (HBR) undergoing transcatheter aortic valve implantation (TAVI) are of major importance, but the lack of standardised definitions is challenging for trial design, data interpretation, and clinical decision-making. The Valve Academic Research Consortium for High Bleeding Risk (VARC-HBR) is a collaboration among leading research organisations, regulatory authorities, and physician-scientists from Europe, the USA, and Asia, with a major focus on TAVI-related bleeding. VARC-HBR is an initiative of the CERC (Cardiovascular European Research Center), aiming to develop a consensus definition of TAVI patients at HBR, based on a systematic review of the available evidence, to provide consistency for future clinical trials, clinical decision-making, and regulatory review. This document represents the first pragmatic approach to a consistent definition of HBR evaluating the safety and effectiveness of procedures, devices and drug regimens for patients undergoing TAVI..
- Published
- 2024
- Full Text
- View/download PDF
23. One-year clinical outcomes of transcatheter aortic valve implantation with the latest iteration of self-expanding or balloonexpandable devices: insights from the OPERA-TAVI registry.
- Author
-
Costa G, Saia F, Pilgrim T, Abdel-Wahab M, Garot P, Sammartino S, Gandolfo C, Branca L, Latib A, Amat-Santos I, Mylotte D, De Marco F, De Backer O, Nombela Franco L, Akodad M, Ribichini FL, Bedogni F, Mazzapicchi A, Tomii D, Laforgia P, Cannata S, Fiorina C, Scotti A, Fezzi S, Criscione E, Poletti E, Mazzucca M, Lunardi M, Mainardi A, Andreaggi S, Quagliana A, Montarello NJ, Hennessey B, Mon-Noboa M, Meier D, Adamo M, Sgroi C, Reddavid CM, Strazzieri O, Crescenzia Motta S, Frittitta V, Dipietro E, Comis A, Melfa C, Calì M, Laterra G, Thiele H, Webb JG, Sondergaard L, Tamburino C, and Barbanti M
- Subjects
- Humans, Aortic Valve diagnostic imaging, Aortic Valve surgery, Treatment Outcome, Registries, Prosthesis Design, Transcatheter Aortic Valve Replacement adverse effects, Aortic Valve Stenosis surgery, Heart Valve Prosthesis adverse effects, Stroke etiology
- Abstract
Background: Midterm comparative analyses of the latest iterations of the most used Evolut and SAPIEN platforms for transcatheter aortic valve implantation (TAVI) are lacking., Aims: We aimed to compare 1-year clinical outcomes of TAVI patients receiving Evolut PRO/PRO+ (PRO) or SAPIEN 3 Ultra (ULTRA) devices in current real-world practice., Methods: Among patients enrolled in the OPERA-TAVI registry, patients with complete 1-year follow-up were considered for the purpose of this analysis. One-to-one propensity score matching was used to compare TAVI patients receiving PRO or ULTRA devices. The primary endpoint was a composite of 1-year all-cause death, disabling stroke and rehospitalisation for heart failure. Five prespecified subgroups of patients were considered according to leaflet and left ventricular outflow tract calcifications, annulus dimensions and angulation, and leaflet morphology., Results: Among a total of 1,897 patients, 587 matched pairs of patients with similar clinical and anatomical characteristics were compared. The primary composite endpoint did not differ between patients receiving PRO or ULTRA devices (Kaplan-Meier [KM] estimates 14.0% vs 11.9%; log-rank p=0.27). Patients receiving PRO devices had higher rates of 1-year disabling stroke (KM estimates 2.6% vs 0.4%; log-rank p=0.001), predominantly occurring within 30 days after TAVI (1.4% vs 0.0%; p=0.004). Outcomes were consistent across all the prespecified subsets of anatomical scenarios (all p
interaction >0.10)., Conclusions: One-year clinical outcomes of patients undergoing transfemoral TAVI and receiving PRO or ULTRA devices in the current clinical practice were similar, but PRO patients had higher rates of disabling stroke. Outcomes did not differ across the different anatomical subsets of the aortic root.- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.